Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q2

4564.TEDINET S100PGWR
Period2022-04-01 → 2022-09-30
Filed2022-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥515m2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥241m2021-04-01 → 2021-09-30Cons.Net sales
Operating income−¥618m2022-04-01 → 2022-09-30Cons.Operating income
Operating income−¥949m2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income−¥644m2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income−¥2.1bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥952m2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax−¥613m2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥1.2bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)−¥614m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.2bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income−¥614m2022-04-01 → 2022-09-30Cons.Profit loss
Net income−¥1.2bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.7bnat 2022-09-30Cons.Assets
Total assets¥2.7bnat 2022-03-31Cons.Assets
Total assets¥3.7bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥340mat 2022-09-30Cons.Liabilities
Total liabilities¥705mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.3bnat 2022-09-30Cons.Net assets
Net assets / equity¥2.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥3.1bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥1.3bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥1.8bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥1.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.8bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow−¥517m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.1bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥468m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥25m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-3.192022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.742022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-13.722021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-6.742021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.722021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio76.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio81.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 29
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥188m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥48m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-09-30−¥382m
—segment totalrevenue2022-04-01 → 2022-09-30¥515m
—segment totalrevenue external2022-04-01 → 2022-09-30¥515m
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥111,000
—segment totalsegment profit2022-04-01 → 2022-09-30−¥430m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥195m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥243m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥234m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥8m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2021-04-01 → 2021-09-30−¥63m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2021-04-01 → 2021-09-30¥6m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2021-04-01 → 2021-09-30¥6m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2021-04-01 → 2021-09-30−¥691m
—segment totalrevenue2021-04-01 → 2021-09-30¥249m
—segment totalrevenue external2021-04-01 → 2021-09-30¥241m
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥8m
—segment totalsegment profit2021-04-01 → 2021-09-30−¥754m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 443
ItemContextValueUnit
LiabilitiesPrior1YearInstant704965000JPY
LiabilitiesCurrentQuarterInstant339697000JPY
Capital stockPrior1YearInstant789114000JPY
Capital stockCurrentQuarterInstant789114000JPY
Capital surplusPrior1YearInstant24793617000JPY
Capital surplusCurrentQuarterInstant24793617000JPY
Retained earningsPrior1YearInstant-23686179000JPY
Retained earningsCurrentQuarterInstant-24299975000JPY
Shareholders equityPrior1YearInstant1896553000JPY
Shareholders equityCurrentQuarterInstant1282756000JPY
Subscription rights to sharesPrior1YearInstant83680000JPY
Subscription rights to sharesCurrentQuarterInstant59567000JPY
Net assetsPrior1YearInstant1980233000JPY
Net assetsCurrentQuarterInstant1342324000JPY
Liabilities and net assetsPrior1YearInstant2685199000JPY
Liabilities and net assetsCurrentQuarterInstant1682021000JPY
Business revenuePrior1YTDDuration240607000JPY
Business revenueCurrentYTDDuration514566000JPY
Cost of salesPrior1YTDDuration218896000JPY
Cost of salesCurrentYTDDuration511296000JPY
Research and development expenses sgaPrior1YTDDuration747814000JPY
Research and development expenses sgaCurrentYTDDuration404229000JPY
Selling general and administrative expensesPrior1YTDDuration222660000JPY
Selling general and administrative expensesCurrentYTDDuration217118000JPY
Business expensesPrior1YTDDuration1189371000JPY
Business expensesCurrentYTDDuration1132644000JPY
Operating incomePrior1YTDDuration-948764000JPY
Operating incomeCurrentYTDDuration-618078000JPY
Interest income noiPrior1YTDDuration120000JPY
Interest income noiCurrentYTDDuration－JPY
Subsidy income noi bountyPrior1YTDDuration389000JPY
Subsidy income noi bountyCurrentYTDDuration－JPY
Interest on refund noiPrior1YTDDuration－JPY
Interest on refund noiCurrentYTDDuration87000JPY
Other noiPrior1YTDDuration0JPY
Other noiCurrentYTDDuration－JPY
Non operating incomePrior1YTDDuration509000JPY
Non operating incomeCurrentYTDDuration87000JPY
Stock issuance cost noePrior1YTDDuration2650000JPY
Stock issuance cost noeCurrentYTDDuration－JPY
Foreign exchange losses noePrior1YTDDuration1140000JPY
Foreign exchange losses noeCurrentYTDDuration9421000JPY
Relocation expenses noePrior1YTDDuration－JPY
Relocation expenses noeCurrentYTDDuration16161000JPY
Non operating expensesPrior1YTDDuration3791000JPY
Non operating expensesCurrentYTDDuration25583000JPY
Ordinary incomePrior1YTDDuration-952046000JPY
Ordinary incomeCurrentYTDDuration-643574000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration49000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass